share_log

宜明昂科(01541.HK)核心產品替達派西普III期臨床試驗方案獲批

AASTOCKS ·  Apr 17 12:34

宜明昂科-B(01541.HK)公布,獲中國國家藥監局對IMM01(替達派西普)與替雷利珠單抗聯用治療程序性細胞死亡蛋白抑制劑治療後復發或病情有所進展的復發性或難治性經典霍奇金淋巴瘤進行III期臨床試驗方案的批准。集團的核心產品IMM01是創新靶向分化簇47的分子。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment